Title:
ヒト癌を処置するのに有用なキメライムノレセプター
Document Type and Number:
Japanese Patent JP2004528848
Kind Code:
A
Abstract:
The present invention relates to chimeric transmembrane immunoreceptors, named "zetakines," comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Ralpha2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.
Inventors:
Jensen, michael
Application Number:
JP2002585615A
Publication Date:
September 24, 2004
Filing Date:
April 30, 2002
Export Citation:
Assignee:
City of Hope
International Classes:
C12N15/09; A61K35/26; A61K39/395; A61P35/00; C07K14/705; C07K14/715; C12N5/08; A61K38/00; A61K39/00; (IPC1-7): C12N15/09; A61K35/26; A61K39/395; A61P35/00; C07K14/705
Attorney, Agent or Firm:
Kazuo Shamoto
Tadashi Masui
Yasushi Kobayashi
Akio Chiba
Hiroyuki Tomita
Reiko Izumiya
Tadashi Masui
Yasushi Kobayashi
Akio Chiba
Hiroyuki Tomita
Reiko Izumiya